Guilin Sanjin Pharmaceutical Co Ltd (002275) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guilin Sanjin Pharmaceutical Co Ltd (002275) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥117.62 Million ≈ $17.21 Million USD) by net assets (CN¥3.24 Billion ≈ $474.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Guilin Sanjin Pharmaceutical Co Ltd (002275) market capitalisation for the company's overall valuation and market capitalisation.
Guilin Sanjin Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Guilin Sanjin Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Guilin Sanjin Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guilin Sanjin Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore Guilin Sanjin Pharmaceutical Co Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CRA International Inc
NASDAQ:CRAI
|
-0.024x |
|
Hengtong Logistic Co Ltd
SHG:603223
|
-0.077x |
|
Metsa Board Oyj B
HE:METSB
|
-0.005x |
|
BLS International Services Limited
NSE:BLS
|
0.211x |
|
Compass Minerals International Inc
NYSE:CMP
|
0.618x |
|
Top Energy Shanxi Co Ltd
SHG:600780
|
0.054x |
|
Hotel Shilla
KO:008770
|
-0.137x |
|
KRN Heat Exchanger and Refrigeration
NSE:KRN
|
0.107x |
Annual Cash Flow Conversion Efficiency for Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024. View 002275 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.01 Billion ≈ $440.42 Million |
CN¥588.33 Million ≈ $86.09 Million |
0.195x | +0.25% |
| 2023-12-31 | CN¥2.82 Billion ≈ $412.21 Million |
CN¥549.25 Million ≈ $80.37 Million |
0.195x | +3.76% |
| 2022-12-31 | CN¥2.81 Billion ≈ $411.68 Million |
CN¥528.67 Million ≈ $77.36 Million |
0.188x | +30.08% |
| 2021-12-31 | CN¥2.84 Billion ≈ $415.55 Million |
CN¥410.24 Million ≈ $60.03 Million |
0.144x | -28.52% |
| 2020-12-31 | CN¥2.96 Billion ≈ $433.00 Million |
CN¥597.99 Million ≈ $87.50 Million |
0.202x | +21.50% |
| 2019-12-31 | CN¥2.82 Billion ≈ $411.99 Million |
CN¥468.29 Million ≈ $68.52 Million |
0.166x | -15.39% |
| 2018-12-31 | CN¥2.81 Billion ≈ $410.70 Million |
CN¥551.73 Million ≈ $80.73 Million |
0.197x | +34.52% |
| 2017-12-31 | CN¥2.65 Billion ≈ $388.35 Million |
CN¥387.82 Million ≈ $56.75 Million |
0.146x | -33.97% |
| 2016-12-31 | CN¥2.43 Billion ≈ $354.94 Million |
CN¥536.85 Million ≈ $78.56 Million |
0.221x | +30.14% |
| 2015-12-31 | CN¥2.34 Billion ≈ $342.87 Million |
CN¥398.50 Million ≈ $58.31 Million |
0.170x | -0.47% |
| 2014-12-31 | CN¥2.32 Billion ≈ $339.57 Million |
CN¥396.53 Million ≈ $58.02 Million |
0.171x | +19.83% |
| 2013-12-31 | CN¥2.20 Billion ≈ $322.38 Million |
CN¥314.16 Million ≈ $45.97 Million |
0.143x | -2.08% |
| 2012-12-31 | CN¥2.08 Billion ≈ $304.06 Million |
CN¥302.59 Million ≈ $44.28 Million |
0.146x | -15.34% |
| 2011-12-31 | CN¥1.98 Billion ≈ $290.15 Million |
CN¥341.05 Million ≈ $49.91 Million |
0.172x | +8.44% |
| 2010-12-31 | CN¥1.80 Billion ≈ $263.37 Million |
CN¥285.49 Million ≈ $41.78 Million |
0.159x | -22.16% |
| 2009-12-31 | CN¥1.78 Billion ≈ $260.89 Million |
CN¥363.29 Million ≈ $53.16 Million |
0.204x | -16.01% |
| 2008-12-31 | CN¥787.10 Million ≈ $115.18 Million |
CN¥190.97 Million ≈ $27.94 Million |
0.243x | +7.63% |
| 2007-12-31 | CN¥729.25 Million ≈ $106.71 Million |
CN¥164.39 Million ≈ $24.06 Million |
0.225x | -35.03% |
| 2006-12-31 | CN¥627.33 Million ≈ $91.80 Million |
CN¥217.67 Million ≈ $31.85 Million |
0.347x | -- |
About Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache … Read more